Results 151 to 160 of about 268,545 (217)

Acceptance, Adherence, and Side Effects of Depot Medroxyprogesterone Acetate: A Prospective Observational Study. [PDF]

Cureus
Rajaraman R, Vaithilingan S, Selvavinayagam TS.   +2 more
europepmc   +1 more source

Serum concentrations of medroxyprogesterone acetate were undetectable on OPU+5 days and had no effect on the serum progesterone level in patients undergoing the progestin-primed ovarian stimulation protocol. [PDF]

Front Endocrinol (Lausanne)
Chen X, Yan X, Xu H, Hu Y, Jiang S, Wang X, Peng H, Feng B, Zhang C, Diao H, Zhang Y.   +10 more
europepmc   +1 more source

Mammary carcinoma in a male cat following long-term medroxyprogesterone acetate treatment: case report and review of the literature. [PDF]

Vet Res Commun
Pîrvu AM, Cappelleri A, Sala L, Banco B, Giudice C, Stefanello D, Militaru M, Grieco V.   +7 more
europepmc   +1 more source

Spatial transcriptomics unveils estrogen-modulated immune responses and structural alterations in the ectocervical mucosa of depot medroxyprogesterone acetate users. [PDF]

Sci Rep
Kaldhusdal V, Boger MF, Tjernlund A, Burgener AD, Bradley F, Lajoie J, Omollo K, Kimani J, Fowke K, Czarnewski P, Broliden K.   +10 more
europepmc   +1 more source

Injection Depot Medroxyprogesterone Acetate as an Early Postpartum Contraceptive Measure: Evaluation of Its Acceptability, Efficacy, and Impact on Lactation. [PDF]

Cureus
Srivastava Garg S, Bhateja B, Grover S, Tapasvi I.   +3 more
europepmc   +1 more source

Medroxyprogesterone acetate in the management of cancer cachexia

Expert Opinion on Pharmacotherapy, 2009
Medroxyprogesterone acetate (MPA) is a synthetic, orally active derivative of the natural steroid hormone progesterone, widely used in oncology both in the endocrine treatment of hormone-related cancers and as supportive therapy in the cachexia syndrome.The anticachectic mechanisms of medroxyprogesterone, beyond its endocrine activity, are described to
Giovanni Mantovani, Clelia Madeddu, Antonio Macciò   +2 more
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

IMMUNOSUPPRESSION WITH MEDROXYPROGESTERONE ACETATE

Transplantation, 1968
The immunosuppressive effects of MPA (medroxyprogesterone acetate) were tested in clinical studies with laboratory dogs and rabbits. The laboratory procedures employed in the studies are explained and results are tabulated and graphed. 2 microscopic photographs illustrate the observed effects.
J G, Turcotte, R F, Haines, G L, Brody, T J, Meyer, S A, Schwartz   +4 more
openaire   +2 more sources

Medroxyprogesterone acetate therapy in hirsutism

British Journal of Dermatology, 1985
In a pilot study, 26 hirsute females were treated with medroxyprogesterone acetate (MPA). We used an ointment containing 0.2% MPA in 13 patients, subcutaneous injection of MPA into the hairy areas of the face in five patients and intramuscular injection of low doses of MPA in 13 patients, each for an average duration of 16 weeks.
J B, Schmidt, J, Huber, J, Spona
openaire   +2 more sources